ALGS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Aligos Therapeutics Inc (ALGS) is not a strong buy for a beginner, long-term investor with $50,000-$100,000 available for investment at this time. The stock is currently in a bearish technical trend, has weak financial performance, and lacks recent positive news or catalysts. While hedge funds are buying, and there is a positive analyst rating with a $20 price target, the lack of immediate positive momentum, poor recent earnings, and absence of Intellectia Proprietary Trading Signals make it prudent to hold rather than buy.
The technical indicators suggest a bearish trend. The MACD is negative and expanding downward, the RSI is at 37.344 (neutral but leaning towards oversold), and the moving averages indicate a bearish alignment (SMA_200 > SMA_20 > SMA_5). The stock is trading below key pivot levels, with support at 6.677 and resistance at 7.403. Overall, the technicals do not support a buy at this time.
Hedge funds are increasing their buying activity significantly (+162.30% last quarter). Analyst Michael Yee from UBS initiated coverage with a Buy rating and a $20 price target, suggesting long-term potential.
No recent news or event-driven catalysts. Financial performance in Q3 2025 was weak, with revenue dropping 41.61% YoY and EPS declining by 0.98% YoY. The stock has a 30% chance of declining further in the next week (-7.13%) and month (-9.48%).
In Q3 2025, revenue dropped significantly by 41.61% YoY to $741,000. Net income improved to -$31.54M (up 63.75% YoY), but EPS dropped slightly to -3.04 (-0.98% YoY). Gross margin remained stable at 100%. Overall, the financials show weak growth trends.
UBS analyst Michael Yee initiated coverage with a Buy rating and a $20 price target, citing an improving biotech sector and long-term potential for ALGS. However, the stock is not among the analyst's top picks, and there are no immediate catalysts highlighted.
